Dr. Bateman’s recent research focuses on learning whether alterations in amyloid beta clearance levels can predict the presence of Alzheimer’s years before symptoms become visible. He led the development of stable isotope-labeling kinetics (SILK), a technique that allowed him and his collaborators to determine that amyloid beta proteins in the brain are not cleared as well in patients with Alzheimer’s disease.
At Washington University School of Medicine, Dr. Bateman is an investigator at the Knight ADRC and the Hope Center for Neurological Disorders. He is listed as an inventor on two patents; several more are pending. He is a scientific co-founder of C2N Diagnostics, a biotechnology company that is working to make the SILK technique available to the broader scientific community.
Dr. Bateman earned the American Academy of Neurology Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases (2019) and is a member of the American Neurological Association and the American Society for Clinical Investigation Council. In 2013, he was a co-recipient of the Washington University Chancellor’s Award for Innovation and Entrepreneurship.
Dr. Bateman earned bachelor’s degrees in biology and electrical engineering from Washington University before earning his medical degree at Case Western Reserve University School of Medicine. He completed a medical internship at Barnes-Jewish Hospital followed by a neurology residency at Washington University. He joined the university’s faculty in 2005.